Franklin Resources’s Trillium Therapeutics Inc. TRIL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-803,339
Closed -$14.1M 2599
2021
Q3
$14.1M Sell
803,339
-2,921,896
-78% -$34.1M 0.01% 972
2021
Q2
$36.1M Buy
3,725,235
+251,830
+7% +$2.37M 0.01% 732
2021
Q1
$37.3M Buy
3,473,405
+26,271
+0.8% +$325K 0.02% 697
2020
Q4
$50.7M Buy
3,447,134
+665,694
+24% +$9.6M 0.02% 589
2020
Q3
$39.5M Buy
2,781,440
+1,266,540
+84% +$12.6M 0.02% 615
2020
Q2
$12.4M Hold
1,514,900
0.01% 828
2020
Q1
$6.12M Buy
+1,514,900
New +$5.73M ﹤0.01% 896
2017
Q3
Sell
-20,200
Closed -$89K 1528
2017
Q2
$89K Sell
20,200
-374,800
-95% -$2.07M ﹤0.01% 1488
2017
Q1
$2.44M Hold
395,000
﹤0.01% 1220
2016
Q4
$2.23M Hold
395,000
﹤0.01% 1214
2016
Q3
$5.84M Hold
395,000
﹤0.01% 1077
2016
Q2
$3.55M Hold
395,000
﹤0.01% 1154
2016
Q1
$3.65M Hold
395,000
﹤0.01% 1154
2015
Q4
$4.98M Hold
395,000
﹤0.01% 1133
2015
Q3
$5.15M Hold
395,000
﹤0.01% 1139
2015
Q2
$8.62M Buy
+395,000
New +$9.01M ﹤0.01% 1069

Other funds holding TRIL

Franklin Resources's TRIL Position: Q4 2021 in Review

Franklin Resources sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 803,339 shares — an estimated $14.1M sold.

Franklin Resources first reported a position in TRIL in Q2 2015 and held it in 16 quarters. The position peaked at $50.7M in Q4 2020. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

  • Franklin Resources reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
  • Franklin Resources sold 803,339 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $14.1M.
  • Franklin Resources first reported a position in Trillium Therapeutics Inc. in Q2 2015 and held it in 16 quarters.
  • Franklin Resources's Trillium Therapeutics Inc. position peaked at $50.7M in Q4 2020.
  • 2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Franklin Resources's 13F filing for Q4 2021, filed 11 Feb 2022.